Tolerance and pharmacokinetics of a new antiulcer compound in man after single oral doses
5-[(2-Diethylamino)ethyl]amino-5,11-dihydro[1]benzoxepino[3,4- b]pyridine trihydrochloride (KW-5805) is a new antiulcer compound, which was effective in animal studies by increasing gastric mucus and stimulating defensive factors such as glucosamine-synthesizing enzymes rather than by inhibiting agg...
Saved in:
Published in | Arzneimittel-Forschung Vol. 39; no. 7; p. 805 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Germany
01.07.1989
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | 5-[(2-Diethylamino)ethyl]amino-5,11-dihydro[1]benzoxepino[3,4- b]pyridine trihydrochloride (KW-5805) is a new antiulcer compound, which was effective in animal studies by increasing gastric mucus and stimulating defensive factors such as glucosamine-synthesizing enzymes rather than by inhibiting aggressive factors. In this placebo-controlled, double-blind study the tolerability and pharmacokinetics of KW-5805 have been evaluated first time in man. Single oral doses of 2.5 to 320 mg were administered to 3 healthy young male subjects per dose level. One additional subject received placebo at each dose level. Plasma and urine samples were collected up to 24 h after administration and analysed gaschromatographically respectively by a high performance liquid chromatography. The mean maximum concentrations in plasma of KW-5805 occurred between 1.17 and 3.33 h after administration, independent of the dose. The half-lives of elimination varied between 6.63 and 11.9 h. 13.4-23.7, 9.6-13.4 and 6.5-11.0% of the administered dose were recovered in the urine after 24 h as unchanged substance, as monodeethylated (M-1) and as hydroxylated (M-3) metabolite, respectively. KW-5805 was not associated with any clinically significant effect on vital signs, ECG or laboratory investigations. Subjectively and objectively the substance was well tolerated in the dose range administered. |
---|---|
AbstractList | 5-[(2-Diethylamino)ethyl]amino-5,11-dihydro[1]benzoxepino[3,4- b]pyridine trihydrochloride (KW-5805) is a new antiulcer compound, which was effective in animal studies by increasing gastric mucus and stimulating defensive factors such as glucosamine-synthesizing enzymes rather than by inhibiting aggressive factors. In this placebo-controlled, double-blind study the tolerability and pharmacokinetics of KW-5805 have been evaluated first time in man. Single oral doses of 2.5 to 320 mg were administered to 3 healthy young male subjects per dose level. One additional subject received placebo at each dose level. Plasma and urine samples were collected up to 24 h after administration and analysed gaschromatographically respectively by a high performance liquid chromatography. The mean maximum concentrations in plasma of KW-5805 occurred between 1.17 and 3.33 h after administration, independent of the dose. The half-lives of elimination varied between 6.63 and 11.9 h. 13.4-23.7, 9.6-13.4 and 6.5-11.0% of the administered dose were recovered in the urine after 24 h as unchanged substance, as monodeethylated (M-1) and as hydroxylated (M-3) metabolite, respectively. KW-5805 was not associated with any clinically significant effect on vital signs, ECG or laboratory investigations. Subjectively and objectively the substance was well tolerated in the dose range administered. |
Author | Kobayashi, S Uckert, B Maier-Lenz, H |
Author_xml | – sequence: 1 givenname: B surname: Uckert fullname: Uckert, B organization: Biodesign GmbH, Institute for Clinical Pharmacology, Freiburg/Brsg., Fed. Rep. of Germany – sequence: 2 givenname: S surname: Kobayashi fullname: Kobayashi, S – sequence: 3 givenname: H surname: Maier-Lenz fullname: Maier-Lenz, H |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/2783183$$D View this record in MEDLINE/PubMed |
BookMark | eNotj8tqwzAURLVISZM0n1DQDxj0tORlCX1BoJt00VW4lq9TtbJkJJvSv6-hWQ0zZxiYLVnFFHFFNowxVSluxC3ZlvLFmGDG8DVZC2Mlt3JDPk4pYIbokELs6PgJeQCXvn3EybtCU0-BRvxZ6OTn4DBTl4YxzUvZRzpApNBPS1p8vASkKUOgXSpY7shND6Hg_qo78v70eDq8VMe359fDw7EahdRTpRCMRm1q65wDpYxSkotOIwCDRrZgGwBu68ZJtN3ijW7bWghkDdc902JH7v93x7kdsDuP2Q-Qf8_Xi-IPKkNO5A |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 2783183 |
Genre | Controlled Clinical Trial Clinical Trial Randomized Controlled Trial Journal Article |
GroupedDBID | --- 0R~ 36B 3O- 4.4 53G 5RE ABCQX ABJNI ACGFS AEIGU ALMA_UNASSIGNED_HOLDINGS CGR CUY CVF EBS ECM EIF EJD EMB EMOBN F5P L7B MK0 NPM O9- P2P RTC SJN SV3 X7J ZGI |
ID | FETCH-LOGICAL-p235t-4ea75e5768ccca44744312d5eaa0a93ba89aa1869c3e8d3ba75bb622e0915f052 |
ISSN | 0004-4172 |
IngestDate | Thu May 23 22:56:57 EDT 2024 |
IsPeerReviewed | false |
IsScholarly | false |
Issue | 7 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p235t-4ea75e5768ccca44744312d5eaa0a93ba89aa1869c3e8d3ba75bb622e0915f052 |
PMID | 2783183 |
ParticipantIDs | pubmed_primary_2783183 |
PublicationCentury | 1900 |
PublicationDate | 1989-07-01 |
PublicationDateYYYYMMDD | 1989-07-01 |
PublicationDate_xml | – month: 07 year: 1989 text: 1989-07-01 day: 01 |
PublicationDecade | 1980 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany |
PublicationTitle | Arzneimittel-Forschung |
PublicationTitleAlternate | Arzneimittelforschung |
PublicationYear | 1989 |
SSID | ssj0020771 |
Score | 1.2120085 |
Snippet | 5-[(2-Diethylamino)ethyl]amino-5,11-dihydro[1]benzoxepino[3,4- b]pyridine trihydrochloride (KW-5805) is a new antiulcer compound, which was effective in animal... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 805 |
SubjectTerms | Adult Anti-Ulcer Agents - administration & dosage Anti-Ulcer Agents - adverse effects Anti-Ulcer Agents - pharmacokinetics Benzoxepins - administration & dosage Benzoxepins - adverse effects Benzoxepins - pharmacokinetics Blood Pressure - drug effects Body Temperature - drug effects Chromatography, Gas Chromatography, High Pressure Liquid Double-Blind Method Electrocardiography Humans Male Pulse - drug effects |
Title | Tolerance and pharmacokinetics of a new antiulcer compound in man after single oral doses |
URI | https://www.ncbi.nlm.nih.gov/pubmed/2783183 |
Volume | 39 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3LT9tAEIdXPITEpWoLqJSC5lBxYis_1l7nWFVEiDZRDokEJ7RrryVEakfBHJK_npndjfMQRdCLlXijKPLnHc9M5jfD2HcRZkpprblM04RGmMVcxbHkKlPoHGuNLjTpnXv99Gokrm-Sm8WAca8uafSPfP6iruR_qOI55Eoq2XeQbb8UT-Br5ItHJIzHtzGux2ba1vxPfBfqB3QcbfNlK31EtxlXm_uncW6mtoKcBilRmoOy925EOOULqMiQxPpF_ejLCtvetPPKkAyqMWPeracYDj_5xx2CGrWqn_a_m99oImY0o2kts9pT-ADmf0w1X0oiCtWWU8lFtmFhQQUXoVyzoK4dkb9T5Io5zKykullBMflrWdB8j9BNsHl1caMXtl_ZZtsyI3PWp9SMj64DKf14RPcD99me__hGxGA9h-FH9sG7_PDT8fvEtkz1mZ0PHK3ZBQyXErjHCziHwbKb-OyA3baQASHDJmSoS1CAkKGFDAvIcF8BQgYLGRxkIMhgIR-yUfdy-OuK-3kYfBLFScOFwf1jKEDMcd8JIQV6f1GRGKUC1Ym1yjpK0YixPDZZge9lonUaRQZ9wqQMkuiI7VR1Zb4wCCNdomcShcqkIigQdKfEQKHMo7jMTaCP2ZG7ZHcT1_Tkzl_Lr_9aOGH7y_vlG9stcY-ZU3TYGn1mQT0D-x5GHA |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tolerance+and+pharmacokinetics+of+a+new+antiulcer+compound+in+man+after+single+oral+doses&rft.jtitle=Arzneimittel-Forschung&rft.au=Uckert%2C+B&rft.au=Kobayashi%2C+S&rft.au=Maier-Lenz%2C+H&rft.date=1989-07-01&rft.issn=0004-4172&rft.volume=39&rft.issue=7&rft.spage=805&rft_id=info%3Apmid%2F2783183&rft_id=info%3Apmid%2F2783183&rft.externalDocID=2783183 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0004-4172&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0004-4172&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0004-4172&client=summon |